The number of wasted COVID-19 vaccines under the national government’s vaccination program went beyond the “acceptable” ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Last Friday, HHS announced it will provide approximately $590 million to Moderna to accelerate the development of mRNA-based ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Nurse practitioner Barbara Huffines administers the Moderna COVID-19 vaccine to EMS and housekeeping employee, Brenda Moore, at the Robley Rex VA Health Center in Louisville on Dec. 22, 2020.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...